Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents

详细信息    查看全文

• 作者：Elias Jabbour ; Stefan Faderl ; Koji Sasaki ; Tapan Kadia ; Naval Daver ; Naveen Pemmaraju ; Keyur Patel ; Joseph D. Khoury ; Carlos Bueso-Ramos ; Zachary Bohannan ; Farhad Ravandi ; Gautam Borthakur ; Srdan Verstovsek ; Darla Miller ; Rita Maduike ; Chitra Hosing ; Hagop M. Kantarjian and Guillermo Garcia-Manero
• 刊名：Cancer
• 出版年：2017
• 出版时间：February 15, 2017
• 年：2017
• 卷：123
• 期：4
• 页码：629-637
• 全文大小：306K
• ISSN：1097-0142

文摘

The outcome of patients with higher-risk myelodysplastic syndromes (MDS) after hypomethylating agent (HMA) failure is poor. This study evaluated the safety and activity of a combination of low-dose clofarabine and cytarabine for these patients.